Tweet
Vaccine
. 2026 May 27:86:128762.
doi: 10.1016/j.vaccine.2026.128762. Online ahead of print.
TLR7 ligand-cyclodextrin conjugate is a promising adjuvant for intranasal influenza vaccine
Ryo Jufuku 1 , Hiroyuki Shinchi 1 , Koki Murata 1 , Michael Chan 2 , Tomoko Hayashi 2 , Howard B Cottam 2 , Dennis A Carson 2 , Yasuo Suda 1 , Masahiro Wakao 3
Affiliations
The development of novel vaccine adjuvants with high efficacy remains an important issue in vaccine design. In this study, we examined a 1 V209-cyclodextrin (CD) conjugate that we have previously developed and evaluated its potential as an adjuvant for intranasal vaccines. Intranasal administration of the vaccines adjuvanted with 1 V209-CD conjugate enhanced both mucosal and systemic IgA and IgG responses against a model antigen, ovalbumin, recombinant hemagglutinin (rHA) from influenza virus strain A/Puerto Rico/8/1934 (H1N1), and a commercially available split influenza vaccine. In an influenza A virus challenge experiment, mice immunized with vaccines adjuvanted with the 1 V209-CD conjugate showed significantly improved survival and reduced lung tissue damage compared with non-adjuvanted controls, indicating that the 1 V209-CD conjugate promoted protective effects. These findings demonstrate that the 1 V209-CD conjugate effectively enhanced immunogenicity of the rHA or existing influenza split vaccine and may serve as a useful adjuvant for intranasal vaccines.
Keywords: 1 V209; Adjuvant; Agonist; Cyclodextrin; TLR7; Vaccine.
. 2026 May 27:86:128762.
doi: 10.1016/j.vaccine.2026.128762. Online ahead of print.
TLR7 ligand-cyclodextrin conjugate is a promising adjuvant for intranasal influenza vaccine
Ryo Jufuku 1 , Hiroyuki Shinchi 1 , Koki Murata 1 , Michael Chan 2 , Tomoko Hayashi 2 , Howard B Cottam 2 , Dennis A Carson 2 , Yasuo Suda 1 , Masahiro Wakao 3
Affiliations
- PMID: 42202427
- DOI: 10.1016/j.vaccine.2026.128762
The development of novel vaccine adjuvants with high efficacy remains an important issue in vaccine design. In this study, we examined a 1 V209-cyclodextrin (CD) conjugate that we have previously developed and evaluated its potential as an adjuvant for intranasal vaccines. Intranasal administration of the vaccines adjuvanted with 1 V209-CD conjugate enhanced both mucosal and systemic IgA and IgG responses against a model antigen, ovalbumin, recombinant hemagglutinin (rHA) from influenza virus strain A/Puerto Rico/8/1934 (H1N1), and a commercially available split influenza vaccine. In an influenza A virus challenge experiment, mice immunized with vaccines adjuvanted with the 1 V209-CD conjugate showed significantly improved survival and reduced lung tissue damage compared with non-adjuvanted controls, indicating that the 1 V209-CD conjugate promoted protective effects. These findings demonstrate that the 1 V209-CD conjugate effectively enhanced immunogenicity of the rHA or existing influenza split vaccine and may serve as a useful adjuvant for intranasal vaccines.
Keywords: 1 V209; Adjuvant; Agonist; Cyclodextrin; TLR7; Vaccine.